リメキソロン

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H360：生殖能または胎児への悪影響のおそれ

• 注意書き

  P201：使用前に取扱説明書を入手すること。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P308+P313：暴露または暴露の懸念がある場合：医師の診断/手当てを 受けること。

リメキソロン 価格

リメキソロン 化学特性,用途語,生産方法

• 効能

  抗炎症薬, グルココルチコイド受容体作動薬

• 説明

  Rimexolone, an ophthalmic corticosteroid, was launched in 1995 in the U.S.A. for the treatment of postoperative inflammation following ocular surgery and anterior uveitis. Rimexolone has high corticoid receptor affinity and is a potent local antiinflammatory agent with minimal systemic effects and virtually no atrophogenic action in many animal models studied, unique among a wide range of topical steroids. Rapid onset, long duration of action plus a superior safety profile are characteristics of rimexolone. It was also approved in Europe for the treatment of rheumatoid arthritis and is currently in clinical trials for tendinitis and osteoarthritis.

• 使用

  Anti-inflammatory (local).

• 一般的な説明

  Rimexolone, 11β-hydroxy-16α,17α-dimethyl-17-(1-oxopropyl)androsta-1,4-diene-3-one,like medrysone and fluorometholone, lacks the C21 OHgroup. In addition, rimexolone has an additional methylgroup in the 17 -position, a site where an OH group is typicallyfound. Rimexolone is available as a suspension forophthalmic use.

リメキソロン 上流と下流の製品情報

リメキソロン 生産企業

Global(61)Suppliers

49697-38-3, リメキソロン キーワード